Nvidia’s Stock Holds Steady as Political and Healthcare Bets Shape the Next Chapter

Nvidia shares hover near 50-day moving average amid strategic hires and healthcare AI deals, signaling a pivot beyond core chip markets.

Nvidia shares closed the week at €177.28, a price that sits almost precisely on the stock’s 50-day moving average of €177.30. The relative strength index of 45.6 sits below the neutral 50 mark, signaling neither panic nor euphoria. On the surface, it looks like a pause — but beneath that calm, the company is quietly repositioning itself for a new phase of growth that extends well beyond the chip market.

A Washington Heavyweight Joins the Team

The most telling move came with the appointment of Bruce Andrews as chief external affairs officer. Andrews is no ordinary lobbyist. He previously ran Intel’s government affairs under Pat Gelsinger and served as a Commerce Department official during the Obama administration. Nvidia is bringing in someone who knows how semiconductor policy is built — and dismantled — inside the Beltway.

The timing is hard to ignore. The U.S. is tightening export controls on advanced AI chips bound for China. Nvidia can still ship its less powerful H200 chips, but those shipments have yet to begin. The gap between regulatory approval and commercial reality is exactly the kind of friction Andrews was hired to navigate. In its own SEC filings, Nvidia has warned that export restrictions on GPUs and AI semiconductors could hurt its ability to sell products abroad, creating structural competitive disadvantages. That language is unusually direct for a risk disclosure.

The stock has already begun pricing in that political headwind. After hitting a 52-week high of €202.50 in mid-May, Nvidia has given back about 8% over the past 30 days. The longer-term trend remains intact — the 200-day moving average sits 9% lower at €162.14, and the stock is still up roughly 10% year-to-date and more than 40% over twelve months — but the short-term momentum has clearly cooled.

Planting a Flag in Healthcare AI

While Washington consumes one part of Nvidia’s attention, another part is focused on a very different arena: the doctor’s office. On June 11, the company announced a partnership with Abridge, a healthcare startup valued at $5.3 billion that already counts more than 300 health systems as clients, including Kaiser Permanente, Johns Hopkins Medicine, and Yale New Haven Health.

Abridge’s app listens to physician-patient conversations and automatically turns them into clinical notes. Under the new deal, Nvidia will provide its open-source Nemotron AI models to build a specialized model for clinical workflows. Nvidia has already participated in multiple Abridge funding rounds through its venture arm, so this partnership deepens a relationship that had been quietly growing.

Healthcare is not a side project for Nvidia. It offers an answer to the question more investors are asking: how long can hyperscaler capital spending keep rising? Microsoft is working with the Mayo Clinic on a medical AI model. OpenAI and Anthropic have launched their own health products. Nvidia, which supplies the chips for almost all of those initiatives, is now securing its own place in the treatment room — not for silicon, but for its open model ecosystem.

The Next Product Wave Is Already Rolling

Meanwhile, the core chip business is gearing up for its next leap. Vera Rubin, the architecture that will succeed Blackwell, is already in full production. Nvidia expects first Rubin-based products to reach partners — including AWS, Google Cloud, Microsoft, Oracle Cloud, and specialized providers like CoreWeave, Lambda, and Nebius — in the second half of 2026. The performance targets are striking: Nvidia says Rubin will deliver 5 times the inference speed and 3.5 times the training speed of Blackwell.

On the last earnings call, management projected that hyperscaler AI capital spending could reach $1 trillion by 2027. Rubin is the product designed to capture that wave. And the company is putting its money where its mouth is: Nvidia raised its quarterly dividend from $0.01 to $0.25 per share — a 25-fold increase that signals deep confidence in its own cash flow.

Analysts See Room to Run — But the Market Is Wary

Of the 62 analysts surveyed by S&P Global, the consensus is a “Strong Buy” with a price target around €258.25, implying upside of roughly 46% from current levels. That level of analyst conviction is striking, yet the stock has been unable to hold its highs. The gap between what the analysts see and what the market is willing to pay tells a story about how differently the same data can be read.

For Nvidia, the next chapter will not be written by chips alone. The Andrews hire acknowledges that regulatory navigation is now a core competency. The Abridge partnership shows that the company is expanding its software ecosystem into verticals where recurring revenue can complement hardware cycles. And Vera Rubin ensures that when the next wave of hyperscaler spending arrives, Nvidia will have the product to catch it.

The stock is waiting. But Nvidia is not.